Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan.

IF 3.6 2区医学 Q2 RHEUMATOLOGY

Journal of Rheumatology Pub Date : 2024-09-15 DOI:10.3899/jrheum.2024-0379

Masataka Kuwana, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Takafumi Suda

引用次数: 0

Abstract

In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).¹ Subsequently, Kuwana et al² reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.².

查看原文本刊更多论文

多发性肌炎或皮肌炎相关间质性肺炎患者使用他克莫司的最新进展：日本上市后监测随访 3 年。

2013 年，日本批准他克莫司用于治疗多发性肌炎（PM）/皮肌炎（DM）患者的间质性肺病（ILD）。1 随后，Kuwana 等人2 报告了一项上市后监测研究的两年中期前瞻性结果，研究发现，PM/DM 相关 ILD 患者对含他克莫司的免疫抑制方案耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Rheumatology 医学-风湿病学

CiteScore

6.50

自引率

5.10%

发文量

285

审稿时长

1 months

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.